Revenue for Pfizer (PFE)
According to Pfizer's latest reported financial statements, the company's current revenue (TTM) is $62.58B USD. Revenue is the total income from selling goods or services before any expenses. Unlike net income (earnings), revenue does not subtract operating costs, taxes, or other charges. Figures are in USD; chart and tables below use historical filings (not a live revenue-per-second estimate).
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
PFE
Currently viewingRevenueSwitch metric
TTM (last 4 quarters)
$62.58B
YoY change
-1.6%
5Y CAGR
+8.5%
Peak year (2022)
$100.33B
Cumulative revenue
$1.50T
Revenue history chart for Pfizer (PFE) from 1985 to 2025
Revenue history table for Pfizer (PFE) from 1985 to 2025
| Fiscal year | Period ended | Reported | Revenue | YoY |
|---|---|---|---|---|
| 2025 | $62.58B | -1.6% | ||
| 2024 | $63.63B | +6.8% | ||
| 2023 | $59.55B | -40.6% | ||
| 2022 | $100.33B | +23.4% | ||
| 2021 | $81.29B | +95.2% | ||
| 2020 | $41.65B | +1.2% | ||
| 2019 | $41.17B | -23.3% | ||
| 2018 | $53.65B | +2.1% | ||
| 2017 | $52.55B | -0.5% | ||
| 2016 | $52.82B | +8.1% | ||
| 2015 | $48.85B | -1.5% | ||
| 2014 | $49.60B | -3.8% | ||
| 2013 | $51.58B | -5.6% | ||
| 2012 | $54.66B | -10.4% | ||
| 2011 | $61.03B | -9.0% | ||
| 2010 | $67.06B | +34.1% | ||
| 2009 | $50.01B | +3.5% | ||
| 2008 | $48.30B | -0.3% | ||
| 2007 | $48.43B | +0.1% | ||
| 2006 | $48.37B | +2.0% | ||
| 2005 | $47.41B | -9.7% | ||
| 2004 | $52.52B | +16.2% | ||
| 2003 | $45.19B | +39.6% | ||
| 2002 | $32.37B | +0.4% | ||
| 2001 | $32.26B | +9.1% | ||
| 2000 | $29.57B | +82.5% | ||
| 1999 | $16.20B | +19.6% | ||
| 1998 | $13.54B | +8.3% | ||
| 1997 | $12.50B | +10.6% | ||
| 1996 | $11.31B | +12.8% | ||
| 1995 | $10.02B | +21.0% | ||
| 1994 | $8.28B | +10.7% | ||
| 1993 | $7.48B | +3.4% | ||
| 1992 | $7.23B | +4.0% | ||
| 1991 | $6.95B | +8.5% | ||
| 1990 | $6.41B | +13.0% | ||
| 1989 | $5.67B | +5.3% | ||
| 1988 | $5.39B | +9.5% | ||
| 1987 | $4.92B | +9.9% | ||
| 1986 | $4.48B | +11.2% | ||
| 1985 | $4.02B | — |
Revenue values are taken from Pfizer's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
The 2025 reading of Pfizer (PFE) revenue is $62.58B – edged down 1.6% year-over-year.
Pfizer revenue has recorded the values shown across consecutive periods, with a +8.5% compound annual growth rate over 2020–2025 (5 years).
Between 2022 and 2025, Pfizer revenue plunged 37.6%, falling from $100.33B to $62.58B.
2022 marks the peak revenue at $100.33B, with the historical low of $4.02B recorded in 1985.
Within Healthcare, Pfizer (PFE) ranks 6th among 8 peers we track. The peer median for revenue is $65.09B.
Pfizer Revenue by Year
Pfizer Revenue 2025: $62.58B
Pfizer revenue in 2025 was $62.58B, edged down 1.6% below 2024.
Pfizer Revenue 2024: $63.63B
Pfizer revenue in 2024 was $63.63B, grew 6.8% from 2023.
Pfizer Revenue 2023: $59.55B
Pfizer revenue in 2023 was $59.55B, plunged 40.6% below 2022.
Pfizer Revenue 2022: $100.33B
Pfizer revenue in 2022 was $100.33B, grew 23.4% from 2021. This figure represents the highest annual value in the available history.
Pfizer Revenue 2021: $81.29B
Pfizer revenue in 2021 was $81.29B.
See more financial history for Pfizer (PFE).
Sector peers — Revenue
Companies in the same sector as Pfizer, ranked by their latest revenue.
| Company | Revenue | Sector |
|---|---|---|
| UnitedHealth Group Incorporated (UNH) | $447.57B | Healthcare |
| Novo Nordisk A/S (NVO) | $309.06B | Healthcare |
| Johnson & Johnson (JNJ) | $94.19B | Healthcare |
| Eli Lilly and Company (LLY) | $65.18B | Healthcare |
| Merck & Co., Inc. (MRK) | $65.01B | Healthcare |
| AbbVie Inc. (ABBV) | $61.16B | Healthcare |
| AstraZeneca PLC (AZN) | $58.74B | Healthcare |
| Amgen Inc. (AMGN) | $36.74B | Healthcare |
Frequently asked questions
What is Pfizer's revenue?
- Latest reported revenue for Pfizer (PFE) is $62.58B (period ending December 31, 2025).
How has Pfizer revenue changed year-over-year?
- Pfizer (PFE) revenue changed -1.6% year-over-year on the latest annual filing.
What is the long-term growth rate of Pfizer revenue?
- Pfizer (PFE) revenue compound annual growth rate is +8.5% over the most recent 5 years available.
When did Pfizer revenue hit its highest annual value?
- Pfizer revenue reached its highest annual value of $100.33B in 2022.
What was Pfizer revenue in 2024?
- Pfizer (PFE) revenue in 2024 was $63.63B.
What was Pfizer revenue in 2025?
- Pfizer (PFE) revenue in 2025 was $62.58B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
PFE Overview
Company profile, financial tools, and key metrics
PFE Revenue Counter
Earns $1,984 every second. See per minute, hour, and day.
PFE Earnings Counter
Earns $246.39 per second net profit. See per minute, hour, and day.
PFE Economic Scale
Exceeds Bolivia's GDP. Compare with world economies.
PFE What If Invested
What if you had invested $1,000? See historical returns from any date.
PFE How It Makes Money
Discover visual breakdown of $62.58B in revenue — where it comes from and where it goes.
PFE Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
PFE Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
PFE Daily Price Character
Steady · 46.3% historical win rate (green days). Streaks & record days.
PFE Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.
PFE Stock Split History
6 splits on record. Dates, ratios, and cumulative multiple.
PFE Dividend Profile
Yield: 6.55%. Safety: 3/8. See full history.
PFE Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
PFE Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.